Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | IRS1 | P35568 | 1/20 | 0.40 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13892301 | 0.84 | LMNA (0.63) | LMNAKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL9034666 | 0.81 | LMNA (0.60) | LMNAKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL289059 | 0.80 | LMNA (0.54) | LMNAKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL9400511 | 0.80 | LMNA (0.58) | LMNAKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL4070446 | 0.78 | LMNA (0.55) | LMNAKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL9032918 | 0.78 | LMNA (0.56) | LMNAKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL9034060 | 0.78 | LMNA (0.56) | LMNAKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL7921928 | 0.77 | LMNA (0.51) | LMNAKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL4759822 | 0.77 | LMNA (0.44) | LMNAKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL420412 | 0.77 | LMNA (0.54) | LMNAKMT2AGAAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| CN-1749252-B | Compounds useful to treat retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2011-06-08 | — | — | CN | disclosed |
| CN-1329378-C | Compounds for the treatment of retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2007-08-01 | — | — | CN | disclosed |
| CN-1749252-A | Compounds useful to treat retroviral infections | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-22 | — | — | CN | disclosed |
| CN-1539825-A | Compounds for the treatment of retroviral infections | �������Ŷ���Լ��������˾ | 2004-10-27 | — | — | CN | disclosed |
| CN-1154642-C | Compounds for the treatment of retroviral infections | �������Ŷ���Լ��������˾ | 2004-06-23 | — | — | CN | disclosed |
| US-6169181-B1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2001-01-02 | — | — | US | disclosed |
| US-5852195-A | Pyranone compounds useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| CN-1150424-A | Compounds for the treatment of retroviral infections | UPJOHN CO (US) | 1997-05-21 | — | — | CN | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | LMNA 75/4885KMT2A 3655/4885GAA 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.